Can oral haloperidol tablets be used to treat agitation and delirium, or are they only appropriate via intramuscular or intravenous routes?

Oral Haloperidol is Effective for Delirium and Agitation

Yes, oral haloperidol tablets can and should be used for treating agitation and delirium—they are not restricted to IM or IV routes. In fact, NICE guidelines explicitly recommend oral haloperidol as first-line treatment for delirium in patients who can swallow 1.

Evidence-Based Dosing Algorithm

For Delirium in Patients Able to Swallow:

Start with haloperidol 0.5-1 mg orally at night and every 2 hours as needed 1. The guidelines provide clear escalation:

• Increase in 0.5-1 mg increments as required
• Maximum 10 mg daily (or 5 mg daily in elderly patients)
• For severe distress or immediate danger: Consider higher starting dose of 1.5-3 mg orally 1
• If agitation persists: Add a benzodiazepine like lorazepam 1

The same dose can be given subcutaneously if oral route becomes unavailable, demonstrating bioequivalence across routes 1.

Route Selection Based on Clinical Context:

Oral route is preferred when:

• Patient can swallow safely
• Cooperation is present or achievable
• Less invasive approach is ethically appropriate

Parenteral routes (IM/IV) are indicated when:

• Patient unable to swallow
• Immediate physical danger requiring faster onset
• Severe agitation precluding oral administration

Key Clinical Considerations

Efficacy Across Routes:

The evidence shows oral haloperidol is therapeutically equivalent to parenteral forms for delirium management 1, 2. ESMO guidelines confirm haloperidol 0.5-1 mg orally as appropriate starting dose for delirium in cancer patients 2. The FDA label confirms oral tablets are indicated for "management of manifestations of psychotic disorders" 3, which encompasses delirium-related agitation.

Important Caveats:

Monitor for extrapyramidal symptoms (EPS), particularly at higher doses 2, 4. Do not use in patients with Parkinson's disease or Lewy body dementia due to EPS risk 2.

QTc prolongation risk exists but is manageable with appropriate monitoring 2, 4. Recent large-scale data (n=9,109 ICU patients) showed haloperidol associated with 31-35% mortality reduction in delirium despite QTc concerns 5.

Formulation matters for adverse events: Parenteral routes (IM/IV) carry significantly higher risk of adverse events compared to oral (OR 7.63-10.17) 4. This supports preferential use of oral route when feasible.

Comparative Safety Profile:

Among medications for severe agitation in geriatric patients, haloperidol showed 16% adverse event rate—lower than midazolam (53%) and comparable to lorazepam (16%) and olanzapine (15%) 4. Notably, no cardiac arrests or torsades de pointes were observed in this systematic review 4.

Practical Algorithm:

1. Assess swallowing ability first
2. If able to swallow: Start oral haloperidol 0.5-1 mg, repeat every 2 hours PRN
3. Titrate up in 0.5-1 mg increments based on response (max 10 mg/day, 5 mg/day if elderly)
4. If inadequate response: Add lorazepam 0.5-1 mg orally
5. If unable to swallow: Switch to subcutaneous/IM route at same dose
6. Monitor: QTc interval, EPS, blood pressure

The notion that haloperidol is "only" for IM/IV use is a misconception. Multiple high-quality guidelines explicitly endorse oral haloperidol as appropriate and effective for delirium and agitation management 1, 2.